Nuvectis announces positive data for NXP900 in a preclinical model of Group 4 medulloblastoma

Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease

Nuvectis Pharma, a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, announced positive data for NXP900 in a preclinical xenograft model of Group 4 Medulloblastoma presented on June 12th, 2022 at SIOPE Brain Tumour Group in Hamburg, Germany, by scientists from the Pediatric Solid Tumour Biology and Therapeutics Team led by Prof. Louis Chesler of The Institute of Cancer Research in London, UK, in collaboration with the Institute of Genetics & Cancer at The University of Edinburgh.

“Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease,” said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. “NXP900’s abilities to inhibit the SRC kinase and to cross the blood-brain barrier have been previously demonstrated, translating into potent and durable tumor growth inhibition in this preclinical model. We believe that these results support further development of NXP900 in Group 4 Medulloblastoma and we are excited about the therapeutic potential of NXP900 in this devastating disease.”

The study was conducted in a mouse model of Group 4 Medulloblastoma. Mice in each group were treated with either vehicle or NXP900 (referred to as eCF506) for 28 days. Treatment with NXP900 resulted in substantial tumor growth inhibition and a survival benefit versus the control.

Medulloblastoma is a primary central nervous system (CNS) tumor that can occur in both children and adults, and it is a leading type of brain cancer in children.